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SUMMARY:
Misoprostol is one of the most important drugs in obstetric practice today. However, because of its uterotonic effects and
consequent adverse effects on the pregnant uterus and foetus, the use of this drug requires extreme caution and very close
monitoring particularly in developing countries. The aim of this update is to review the pharmacokinetics and the physiology of
misoprostol and to familiarise fellow practitioners with information and evidence concerning this medication as it is currently
available for use in obstetric practice.
KEY WORDS: Misoprostol update - Current obstetric practice.
MISE A JOUR SUR L’UTILISATION  DE MISOPROSTOL EN OBSTETRIQUE.
RESUME:
Misoprostol est l’un des médicaments le plus important dans la pratique courante en obstétrique. Mais à cause de ses effets
utérotoniques et ses conséquences néfastes sur l’utérus gravide et le fétus, l’utilisation de ce médicament demande des précautions
extrêmes et des monitorings attentifs surtout dans les pays en voie de développement. Cette mise à jour a pour but de rappeler
la pharmacocinétique et la physiologie de misoprostol et de fournir aux confrères médecins les informations et les évidences
concernant l’utilisation de ce produit en obstétrique.
MOTS CLES: Mise à jour sur misoprostol - Pratique courante en obstétrique.
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I- INTRODUCTION
Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analogue that is used in thetreatment of active gastric and duodenal
ulcers and in the prevention and treatment of gastric
ulcers associated with the use of anti-inflammatory
non- steroidal agents [1]. However, because of its
uterotonic and cervical ripening actions, misoprostol
has become a very useful drug in obstetrics and
gynaecology. Misoprostol is currently in wide use
in Cameroon although there is yet no licence by the
Ministry of Public health for its use. The aim of this
update is to familiarise fellow practitioners with in-
formation and evidence concerning misoprostol as
it is currently recommended for use in obstetric prac-
tice.
Misoprostol is used in obstetrics and
gynaecology for elective medical abortions, evacu-
ation of the uterus in cases of missed abortions or
intra-uterine deaths, induction of labour and in the
prevention and treatment of postpartum haemorrha
ge.
II- PHARMOKINETICS
Misoprostol is available for oral, vaginal and
rectal use in the form of 100ì g unscored and 200ì g
scored tablets in the United States. However, in
Cameroon only the 200ì g form is available and it is
manufactured by Monsato France SA (Division
Searle). After oral administration, misoprostol is rap-
idly absorbed and converted to its pharmacologically
active metabolite, misoprostol acid. The plasma con-
centration of misoprostol reaches its peak within 30
minutes but rapidly declines thereafter [2]. Concomi-
tant ingestion of foods or antacids decrease the bio-
availability of misoprostol after oral ingestion. It is
primarily metabolised in the liver but less than 1%
of misoprostol acid is excreted in urine [3].
Misoprostol has no known drug interactions and does
not induce the hepatic cytochrome P-450 enzyme
system. Therefore whilst patients with liver disease
should be given a reduced dose of the drug when
necessary, patients with renal impairment who are
not on dialysis do not require dose adjustments [3].
The side effects of misoprostol are dose depen-
dent and they include nausea, vomiting, diarrhoea,
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abdominal pains, chills, shivering and fever.
Unlike other prostaglandins (E2 and E2á), misoprostol
does not cause myocardial infarction [4]. There is
not much known about the toxicity of misoprostol.
The evidence so far seems to suggest that misoprostol
can only be toxic at extremely high doses. For in-
stance, cumulative doses of up to 2200ì g adminis-
tered over a period of 12 hours have been tolerated
by pregnant women without any serious adverse ef-
fects [5]. However, it has been shown that 6000ì g
of misoprostol, taken orally to induce an abortion
(in conjunction with trifluoperazine), could result
in abortion, hyperthermia, rhabdomyolysis,
hypoxaemia, and a complex acid-base disorder [6].
III- PHYSIOLOGY
Taken orally, misoprostol increases the activi-
ties of the reproductive tract. However when admin-
istered vaginally, these adverse effects are greatly
reduced [7-8]. When misoprostol tablets are placed
in the posterior fornix of the vagina, plasma con-
centrations of misoprostol acid peak in one to two
hours and thereafter decline slowly over 3 to 4 hours
[2]. It has been shown that whereas uterine contrac-
tility initiated after an oral dose plateaus after one
hour, uterine contractility increases continuously for
4 hours after vaginal administration. In fact, maxi-
mal uterine contractility has been shown to be sig-
nificantly higher after vaginal than after oral admin-
istration [7].
IV- TERATOGENICITY
Mobius’ syndrome (congenital facial paralysis)
and limb defects have been reported in the infants
of some women, who took misoprostol during the
first trimester in an unsuccessful attempt to induce
abortion [9,10]. However, the absolute risk of Mo-
bius’ syndrome is probably low among all women
exposed to misoprostol in the first trimester [10].
Other possible teratogenic effects of misoprostol
include transverse limb defects, ring-shaped constric-
tions of the extremities, arthrogryposis, hydroceph-
alus, holoprosenphaly and extrophy of the bladder
[11].
It is worth mentioning that other drugs used in
combination with misoprostol for induction of abor-
tion in the first trimester may also be teratogenic.
Such teratogenic effects have been found to be more
commonly associated with methotrexate than with
mifepristone or misoprostol [12] and include cran-
iofacial and digital anomalies [13,14].
V- INDICATIONS
1- Use of misoprostol in the first trimester of preg-
nancy
- Misoprostol in the management of first trimester
abortions
Misoprostol is used extensively in the first tri-
mester of pregnancy in combination with either
mifepristone or methotrexate for medical abortions.
The role of mifepristone or methotrexate in first tri-
mester pregnancy terminations is to ‘destabilise’ the
ongoing pregnancy whilst that of misoprostol is to
expel the products of conception. Various oral com-
bination regimens of mifepristone given at variable
intervals followed by misoprostol have been de-
scribed [15-19]. In general, misoprostol is more ef-
fective in inducing abortions in the first trimester
when administered vaginally than orally [20]. In fact,
some of these regimens have been self-administered
at home with equal efficacy [21]. When methotrex-
ate is used instead of mifepristone, the rate of com-
plete abortion is often lower and there is often a need
for repeated doses [22-23]. The majority of studies
on medical abortions in the first trimester with ei-
ther mifepristone or methotrexate and misoprostol
have been carried out on women who were no more
than 63 days pregnant. The younger the pregnancy,
the higher the rate of complete abortion
[17,19,23,24]. Misoprostol alone is much less ef-
fective in inducing first trimester abortions [25,26].
The effectiveness of  vaginal misoprostol regimens
in achieving complete abortion in the first trimester
is not affected by whether the tablets are moistened
or dry [27]. Given the inconsistency of complete
abortion rates when vaginal misoprostol is used
alone, as well as the existence of safe alternative
regimens, it is not recommended for medical abor-
tions in the first trimester [28].
- Misoprostol in the management of failed
pregnancies and missed abortions
Failed pregnancies are mainly cases of blighted
ova. In such cases and in cases of missed abortions,
the pregnancy is already destabilised and the physi-
ological changes that eventually lead to a spontane-
ous expulsion are under way (such as placental de-
generation and decidual sloughing). If spontaneous
abortion is delayed, drug therapy may be indicated
to evacuate the uterus in order to avoid surgery or
prolonged wait for expulsion. Misoprostol alone is
sufficient and effective in evacuating the uterus in
such cases [29-31].
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It has been shown that 400ì g of misoprostol
given orally or 800ì g administered vaginally in 2
doses with 24 to 48 hours interval between the two
doses is sufficient to completely evacuate the uterus
in most cases of failed pregnancies without exces-
sive bleeding [29]. Misoprostol has also been shown
to be useful for the treatment of incomplete abor-
tions [32]. However, medical evacuation of the uterus
in cases of incomplete abortions is associated with
considerable blood loss when compared with surgi-
cal evacuations [32]. For this reason misoprostol is
not recommended for the treatment of inevitable or
incomplete abortion [28].
- The role of misoprostol in the ripening the cervix
prior to surgical abortions
Ripening the cervix prior to surgical abortions
in the first trimester significantly reduces the risk of
cervical lacerations and perforation of the uterus at
the time of abortion [33, 34]. Four hundred micro-
grams of misoprostol inserted vaginally has been
shown to be more effective than oral misoprostol in
ripening the cervix before abortions [35]. Doses
higher than 400ì g have been shown to be associ-
ated with more side effects such as fever, vaginal
bleeding and products of conception clogging the
cervical os [35]. The best regimen for cervical rip-
ening in the first trimester is 400ì g inserted vagi-
nally 3 to 4 hours before suction evacuation [28].
2- Use of misoprostol in the second trimester of
pregnancy
A pregnancy in the second trimester may be ter-
minated for maternal medical reasons, severe foetal
abnormalities, foetal deaths and electively. The
uterus can be emptied early in the second trimester
by suction evacuation. However, in late second tri-
mester, the uterus can only be emptied by cervical
dilatation and extraction of the foetus  or by induc-
tion of labour. Misoprostol can ripen the cervix and
can also induce labour during the second trimester
of pregnancy [36,37]. In general, the uterus becomes
more sensitive to uterotonic agents as the gestational
age increases. For instance, a dose of misoprostol
may be sufficient to induce labour in the second but
not in the first half of the second trimester. It has
been noticed that inductions tend to proceed more
rapidly when the foetus is dead than when labour is
induced for other reasons [38,39].
During the first trimester, up to 800ì g  of vagi-
nal misoprostol is required to successfully induce
an abortion. In the third trimester, doses in the range
of 25 to 50ì g induce labour. However in the second
trimester, the dose of misoprostol required to induce
labour probably lies somewhere between 50 and
800µg. Within this range, higher doses may be
needed to cause abortions early in the second tri-
mester, whereas lower doses may be sufficient later
in the second trimester.
Using the usual regimen for induction of labour
in the second trimester of 200ì g of misoprostol given
vaginally every 12 hours, the rate of successful abor-
tion is more than 71% [38-40]. Increasing the fre-
quency of misoprostol administration does not in-
crease the efficacy. However, when doses of 400ì g
of misoprostol is administered vaginally every 3
hours (up to a maximum of 5 doses within 24 hours)
yields a better result of over 91% complete abortion
within 48 hours [41]. Increasing the vaginal dose of
misoprostol to 600µg with the aim of improving the
rate of complete abortion is associated with higher
rates of adverse effects such as fever, nausea, vom-
iting and diarrhoea [40].
The risk of uterine rupture associated with in-
duction of labour with misoprostol in the second tri-
mester is not known because most trials of
misoprostol for induction of labour in the second
trimester have excluded women with uterine scars.
However, uterine rupture can occur whether the
uterus has been previously scarred or not. For in-
stance, uterine rupture during induction of labour
with misoprostol has been reported in a primigravida
with no previous uterine scar [42]. Although the
optimal regimen has not been determined, it appears
that 200 to 600ì g of misoprostol given vaginally
every 12 hours or 400ì g given vaginally every 3
hours successfully induces labour in the second tri-
mester [28]. Such inductions are more successful if
mifepristone is given 36 to 48 hours before
misoprostol [5,43,44]. The evidence in support of
the use of misoprostol to induce labour in the sec-
ond trimester in the presence of a previous scar is
insufficient to recommend its routine use [28].
3- The role of misoprostol in the third trimester of
pregnancy
- Misoprostol and induction of labour when the
foetus is viable
Studies have shown that misoprostol given vaginally
for induction of labour at term is superior to placebo
in ripening the uterine cervix [45,46]. Similarly,
misoprostol alone is effective for inducing labour at
term but its major limiting factor is uterine hyper
stimulation with associated foetal heart rate changes
often resulting in caesarean section with (or without)
adverse foetal and/or maternal outcomes [47,48].
The truth is that adverse outcomes associated with
misoprostol use at term are so few that that the
relative risk of adverse outcomes with the use of
misoprostol for induction of labour remains
unknown [28].
     Concerning a safe (in terms of rate of uterine
hyper stimulation with foetal heart rate changes,
caesarean delivery rate, Apgar scores, admissions
into neonatal intensive care unit and passage of
Update on the use of misoprostol in current obstetric practice.
 
Clinics in Mother and Child Health Vol 3, N° 1,  April 2006486
meconium) and effective (induction-delivery
interval) dose and regimen of misoprostol for
induction of labour at term when the foetus is viable
seems to be 25ì g administered vaginally every four
to six hours [28,49].
- Misoprostol and induction of labour in cases of
intra-uterine deaths
   Misoprostol is particularly suitable for inducing
labour in cases of intra-uterine deaths because there
is no concern about the adverse effects of uterine
hyper stimulation on the foetus. It has been shown
that a dose of 100ìg administered vaginally every
12 hours is very adequate [50,51]. However, a
slightly higher dose (200ìg) may be necessary early
in the third trimester. In fact, for intra-uterine deaths
at term, a dose as low as 50ìg administered intra-
vaginally every 12 hours may be quite sufficient.
- Misoprostol and induction of labour in women
with previous caesarean delivery
     There have been several reports of uterine
rupture associated with the administration of
misoprostol for induction of labour in women
attempting vaginal delivery after previous caesarean
section [52-55]. In fact, one randomised trial to
induce labour in women with one previous
caesarean scar using 25µg of misoprostol inserted
vaginally had to be discontinued because uterine
rupture occurred in two women in the misoprostol
group [53]. A similar disastrous result was noted in
a case control study in which 5.6 % of symptomatic
uterine rupture was noted in the control as against
0.2% in the study group which was undergoing a
trial of labour without the administration of
misoprostol (p<0.001) [56 ]. Notably in that study,
there was no uterine rupture in any of the women
who had undergone caesarean delivery after labour
had begun spontaneously.
It is still not clear why the uterus ruptures in the
presence of a previous scar when misoprostol is
used. Does the use of misoprostol per se in such
circumstances increase the frequency of uterine
rupture or would uterine rupture occur when any
other drug is used to induce labour when the cervix
is unfavourable? In fact, until the answers to such
questions as these are found and misoprostol is
proved safe, misoprostol should not be used to
induce labour in the presence of previous uterine
scars [28].
- Misoprostol and the control of postpartum
haemorrhage
Because of its uterotonic effects, there have
been attempts to use misoprostol to prevent and treat
postpartum haemorrhage. In a prospective observa-
tional study involving 237 women, 600ì g of
misoprostol given orally just after clamping the um-
bilical cord was associated with an estimated blood
loss of 500 ml or more in 6% of women; none of the
women had blood loss of 1000 ml or more [57]. Sub-
sequently, three randomised trials involving a total
of 1115 women examined the efficacy of misoprostol
in the prevention of postpartum haemorrhage [58-
60]. These trials evaluated a dose of 400ì g of
misoprostol given rectally or a dose of 400  to 600ì g
given orally. The frequency of postpartum
haemorrhage (defined as blood loss >1000 ml) was
not lower in the misoprostol group than in the con-
trol group in any of the trials. However, in all three
trials (two of which were blinded), oxytocin was
given to more women in the control groups [58-60].
Thus there is currently insufficient evidence to sup-
port the routine use of misoprostol to prevent post-
partum haemorrhage when oxytocin and methergin
are available, but misoprostol  may lower the inci-
dence of postpartum haemorrhage if these drugs are
not readily available [28].
VI- CONCLUSION
Misoprostol is one of the most important drugs
in obstetric practice today. However, because of its
uterotonic effects and consequent adverse effects on
the pregnant uterus and foetus,  the use of this drug
requires caution and very close monitoring  particu-
larly in developing countries [61,62].
VII- RECOMMENDATIONS
Misoprostol is currently in use in Cameroon
without license from the Ministry of Public Health.
However, data from clinical trials provide strong and
consistent support for its use in obstetric practice.
On the basis of available evidence, misoprostol
should be used as follows:
-  In the first trimester of pregnancy, vaginal
misoprostol alone should not be used for medical
abortions unless it is associated with either
mifepristone or methotrexate.
-  Vaginal misoprostol alone is sufficient and effective
in evacuating the uterus in cases of failed pregnancies
(blighted ovum) during the first trimester. However,
it is not recommended for evacuating the uterus in
cases of inevitable or incomplete abortions.
-  Misoprostol administered vaginally is suitable for
ripening the cervix prior to surgical evacuation of
the uterus in the first trimester.
-  Misoprostol alone administered vaginally is
sufficient and effective in evacuating the uterus in
cases of missed abortions in the second trimester.
However, the evidence in support of its use to induce
labour in the second trimester in the presence of a
previous scar is insufficient at the moment to
recommend its routine use for this purpose.
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- Misoprostol is recommended for induction of
labour at term when the foetus is viable. The safe
and effective dose recommended is 25ìg inserted
vaginally every 4 to 6 hours until labour is well
established; up to a maximum of 6 doses.
- Misoprostol is particularly suitable for inducing
labour in cases of intra-uterine deaths at term. A dose
as low as 50ìg administered vaginally every 12 hours
has been found to be quite adequate.
- Since it is not clear why the uterus tends to
rupture when misoprostol is used to induce labour
in the presence of a previous uterine scar, it should
not be used to induce labour in the presence of
previous uterine scars.
- There is currently insufficient evidence to
support the routine use of misoprostol to prevent
postpartum haemorrhage when oxytocin and
methergin are available, but misoprostol may lower
the incidence of postpartum haemorrhage if these
drugs are not readily available
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